NCT03886025 Combined Anodal Transcranial Direct Current Stimulation (tDCS) and Cognitive Training and Decision-making
| NCT ID | NCT03886025 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Najat Khalifa |
| Condition | Impulsivity |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-09-15 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2022-09-15 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to (i) assess the effects of combined tDCS and cognitive training on decision-making on a trained task (Iowa Gambling Task; IGT); and (ii) test generalization to a closely related cognitive domain, namely motor impulsivity. It is hypothesized that combined anodal tDCS and cognitive training will result in more advantageous decisions and better impulse control than combined sham tDCS and cognitive training.
Eligibility Criteria
Inclusion Criteria: * Consenting volunteers aged between 18 and 40. Exclusion Criteria: * Individuals with epilepsy, other neurological conditions and history of significant head injury will be excluded. * Individuals with a history of substance misuse, major mental disorder and those receiving psychotropic medication will be also excluded.
Contact & Investigator
Najat Khalifa, MD
PRINCIPAL INVESTIGATOR
Queen's University - Canada
Frequently Asked Questions
Who can join the NCT03886025 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Impulsivity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03886025 currently recruiting?
Yes, NCT03886025 is actively recruiting participants. Contact the research team at nrk2@queensu.ca for enrollment information.
Where is the NCT03886025 trial being conducted?
This trial is being conducted at Kingston, Canada.
Who is sponsoring the NCT03886025 clinical trial?
NCT03886025 is sponsored by Dr. Najat Khalifa. The principal investigator is Najat Khalifa, MD at Queen's University - Canada. The trial plans to enroll 60 participants.